Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Biologics in Systemic Sclerosis

Author(s): Jingxiu Xuan, Long Shen, Chongjie Zhang and Julian L. Ambrus Jr.

Volume 15, Issue 6, 2014

Page: [549 - 557] Pages: 9

DOI: 10.2174/138920101506140910150749

Price: $65

Abstract

Systemic sclerosis (scleroderma) is a heterogeneous autoimmune disorder characterized by collagen overproduction that leads to cutaneous and internal organs sclerosis and pulmonary arterial hypertension. SSc has high morbidity and mortality. SSc pathogenesis is uncertain. At present most therapies of SSc are symptomatic. Effective therapeutic approaches are lacking. Accompanying a growing understanding of SSc pathogenesis, various key mediators are being evaluated as the therapeutic targets. This review described the effects of these key mediators in SSc.

Keywords: Antibodies, biologics, fibrosis, pathogenesis, systemic sclerosis.


Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy